Document is current

Article History

Accepted: 4 November 2024

First Online: 5 December 2024

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: E. De Corso received lecture fees and participated to advisory boards for Sanofi, GSK, Regeneron, Astrazeneca. P. W. Hellings has received unrestricted research grants from Sanofi/Regeneron, Viatris and GSK, and honoraria for lectures and/or advisory boards by Sanofi/Regeneron, GSK, and AstraZeneca. W. J. Fokkens received consultation and/or speaker fees from Dianosic, GSK, Menarini, Novartis, Sanofi-Aventis/Regeneron and AstraZeneca. The department of Otorhinolaryngology of the Amsterdam University Medical Centre, location AMC, received grants for research in Rhinology from: Novartis, EU, GSK, and Sanofi-Aventis. L. Klimek reports grants from Allergopharma, MEDA/Mylan, ALK Abelló, LETI Pharma, Stallergenes, Sanofi, ASIT biotech, Lofarma Quintiles, AstraZeneca, GSK, and Inmunotk; and personal fees from Allergopharma, MEDA/Mylan, HAL Allergie, LETI Pharma, Sanofi, Allergy Therapeut, and Cassella Med, outside the submitted work. A. T. Peters has received research grants from Sanofi/Regeneron and AstraZeneca. She has served as a consultant for GSK, Chiesi, Merck, Sanofi Regeneron, Eli Lilly and AstraZeneca. G. K. Scadding received honoraria for articles, speaker and advisory boards: ALK, Bayer, Chiesi, GSK, Haleon, Noucor, Sanofi- Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Vice President and AR lead for EUFOREA, and Chair/ member Data Monitoring Committees on SLIT for ALK. M. Desrosiers received fee for consultation, speaker activity, advisory board by sanofi/ Regeneron, GSK. He also received research support from Sanofi/Regeneron, GSK. Equity holder, Probionase Therapies Inc. S. E. Lee has received clinical trial funding and served on advisory boards for AstraZeneca, Genentech, Lyra Therapeutics, GSK, Optinose, Sanofi Regeneron, Upstream Bio and holds equity in Diceros Therapeutics. J. Mullol reports personal fees and other from SANOFI-GENZYME & REGENERON, personal fees and other from NOVARTIS, grants, personal fees and other from VIATRIS / MEDA Pharma, grants and personal fees from NOUCOR / URIACH Group, personal fees from Menarini, personal fees from UCB, personal fees and other from AstraZeneca, grants, personal fees and other from GSK, personal fees from MSD, personal fees and other from Lilly, personal fees and other from GLENMARK, outside the submitted work. J. Mullol is a Section Editor of Current Allergy and Asthma Reports and was not involved in the peer-review or handling of the manuscript.